Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to $8.9 billion.

  • Sanofi's Cash & Equivalents rose 1210.44% to $8.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.9 billion, marking a year-over-year increase of 1210.44%. This contributed to the annual value of $8.7 billion for FY2025, which is 744.4% up from last year.
  • Sanofi's Cash & Equivalents amounted to $8.9 billion in Q4 2025, which was up 1210.44% from $10.4 billion recorded in Q3 2025.
  • In the past 5 years, Sanofi's Cash & Equivalents registered a high of $16.8 billion during Q2 2021, and its lowest value of $6.9 billion during Q1 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $9.4 billion (2023), whereas its average is $10.1 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 6138.58% in 2021, then plummeted by 3833.53% in 2023.
  • Over the past 5 years, Sanofi's Cash & Equivalents (Quarter) stood at $11.6 billion in 2021, then grew by 12.48% to $13.0 billion in 2022, then fell by 27.88% to $9.4 billion in 2023, then decreased by 15.15% to $8.0 billion in 2024, then grew by 12.1% to $8.9 billion in 2025.
  • Its Cash & Equivalents was $8.9 billion in Q4 2025, compared to $10.4 billion in Q3 2025 and $8.4 billion in Q2 2025.